J&J axes Bavarian Nordic pact for HPV and Hep B vax, keeps two other programs LogicBio's sun and shares rise again after FDA releases clinical hold on pediatric genome editing therapy Another Oxurion eye disease drug flunks phase 2, leaving biotech all-in on last prospect Sesen Bio reports progress with regulators as it preps for new cancer trial, but issues remain Investors take root in Aspen Neuroscience’s customized cell therapy as $147.5M round closes Most influential people in biopharma—the scientists 2,000 Cedars-Sinai Medical Center workers launch five-day strike Biogen syncs up with MedRhythms for music-based walking app in MS Seagen CEO Clay Siegall put on leave amid domestic violence investigation UnitedHealth was this quarter's most profitable payer—again Insulet to swap CEOs amid Omnipod 5 insulin pump rollout Featured Story | By Max Bayer J&J is taking the cleaver to its Bavarian Nordic-partnered HPV and hepatitis B programs, both of which had yet to produce clinical assets. But the Big Pharma is still holding onto its HIV and Ebola collaborations. read more |
| |
|---|
|
Top Stories By Annalee Armstrong The sun and shares are rising again at LogicBio after the FDA lifted a clinical hold on a gene editing therapy for children with a rare disorder. Shares of the Lexington, Masschusetts-based biotech were sent skyward by 60% as the markets opened Monday morning. read more By Nick Paul Taylor Oxurion is left with one last shot at success. The latest drug candidate to flounder in the clinic is THR-687, a pan RGD integrin antagonist that failed a midphase eye disease trial, dragging Oxurion's stock down 40% to 0.60 euro cents ($0.63). read more By Max Bayer Sesen Bio said it's mostly aligned with the FDA on expectations of a new phase 3 trial of its cancer drug, but outstanding issues remain. The update comes days after the company said it was open to a financial escape route to keep afloat. read more By Gabrielle Masson Aspen Neuroscience, a biotech developing the first autologous neuron replacement for Parkinson’s disease, is seeing double, as investors have flooded the company's series B with $147.5 million following an initial $70 million round two years ago. read more By Eric Sagonowsky,Kevin Dunleavy,Max Bayer,Andrea Park,Gabrielle Masson Without science, biopharma wouldn't exist. Without new, groundbreaking science, it might exist, but it wouldn't be very exciting—and it certainly wouldn't be a trillion-dollar enterprise. That's why our look at this year's most influential people had to turn to scientists next. read more By Dave Muoio Cedars-Sinai is the latest California provider organization to face demonstrations from healthcare workers calling for higher wages and safer workplace policies. read more By Conor Hale Biogen is looking to employ a music-based digital therapeutic to help improve the strides of multiple sclerosis pateints who may have trouble walking. read more By Angus Liu Seagen’s co-founder Clay Siegall, Ph.D., has been put on a leave of absence after an alleged incident of domestic violence that happened at his home. read more By Paige Minemyer Each of the six major national payers exceeded Wall Street's expectations for profit in the first quarter, with UnitedHealth Group out in front as the most profitable company. read more By Conor Hale Shacey Petrovic, who served as Insulet’s president and chief executive since 2019, will be stepping down June 1 for personal family reasons. She will be replaced by ResMed's Jim Hollingshead. read more Resources Sponsored by: Catalent In this executive summary, we describe the benefits of controlled release, look at how to determine whether a drug is suitable for controlled release, review the application of PBPK modelling in controlled release formulation development and discuss how modified release products can be developed to deliver optimal patient outcomes. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next Gen June 29-30, 2022 | Free Virtual Event Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 